Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes
Authors' conclusion
Subcutaneous GLP-1 administration is much less efficient than intravenous GLP-1 in lowering fasting plasma glucose, with less stimulation of insulin and suppression of glucagon, and much less bioavailability, even at fourfold higher infusion rates.
Study context
- Population
- Fasted, hyperglycaemic subjects with T2D naïve to GLP-1-based therapy (1 female, age 63 ± 10 years, HbA1c 73.5 ± 22.0 mmol/mol [8.9% ± 2.0%], mean ± SD)crossover
- Participants
- 10 participants
- Comparison
- Subcutaneous vs intravenous GLP-1
- Primary endpoint
- Plasma glucose lowering
- Follow-up
- Over 8 h
Methodological detailsdouble-blind
- Double-blind
Primary result
As reported in the abstract
Decrease in plasma glucose
P < 0.001
Further findings
Total GLP-1 ∆max
P < 0.001
Intact GLP-1 ∆max
P < 0.001
- GLP-1 clearance · total GLP-1 clearance higher with subcutaneous
- P < 0.001
- GLP-1 clearance · intact GLP-1 clearance higher with subcutaneous
- P = 0.002
- Total GLP-1 ∆max: Plasma GLP-1 increased dose-dependently
Insulin secretion and glucagon
- Greater increase in insulin secretion and more glucagon suppression with intravenous GLP-1 (p < 0.05 each)
Safety
- Gastrointestinal symptoms did not differ (p > 0.05 each)
Original publication
Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes. Diabetes Obes Metab. Published 1 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →